FDA Accepted Resubmission for Tabelecleucel

The FDA has accepted a new application for the cancer immunotherapy drug with a decision expected by March 31, 2027.

Updated on Oct. 14, 2026 in Cancer

FDA Accepted Resubmission for Tabelecleucel

Live Poll

Should the FDA be more flexible when approving treatments for ultra-rare diseases?

The FDA has accepted the resubmitted Biologics License Application for tabelecleucel, an immunotherapy targeting Epstein-Barr virus-positive post-transplant lymphoproliferative disease. Regulators have set a target action date of March 31, 2027, for the final decision.

Why it matters

If approved, tabelecleucel would become the first FDA-authorized treatment for this specific type of relapsed or refractory disease. The move follows a successful alignment reached between the manufacturer and the FDA during a Type A meeting held in April 2026.

The ALLELE clinical study reported an overall objective response rate of 47.7% for participants. Patients received intravenous infusions of 2 million cells per kilogram during the trial.

The players

Pierre Fabre Pharmaceuticals

This is a global pharmaceutical company responsible for the development and regulatory submission of the immunotherapy drug tabelecleucel.

FDA

The Food and Drug Administration is the federal agency responsible for overseeing the safety and efficacy of medical products in the United States.

The details

Tabelecleucel is designed to identify and destroy cells infected with the Epstein-Barr virus, addressing a condition that currently carries a median survival of only weeks for patients whose prior treatments failed. The manufacturer, Pierre Fabre Pharmaceuticals, resubmitted the application following two previous complete response letters issued by the FDA.

January 15, 2025: The FDA issued the first complete response letter.
January 9, 2026: The FDA issued the second complete response letter.
April 2026: A Type A meeting was held between the company and the FDA.
March 31, 2027: The FDA target action date for the current application.

Health Landscape

The FDA's complete response letter process remains a rigorous barrier for new drug approvals in oncology, and this resubmission follows that established regulatory pattern. This move highlights the complex path for immunotherapy development compared to existing international authorizations in Europe and the United Kingdom.

Patients currently facing relapsed or refractory disease have very limited options, with existing survival rates measured in weeks. This regulatory update moves the potential treatment one step closer to becoming a standard medical option in the United States.

The takeaway

This development represents a critical milestone in the effort to bring specialized immunotherapy to patients with severe post-transplant complications. The upcoming decision in 2027 will determine if US patients gain access to a treatment already approved in Europe, the United Kingdom, and Switzerland.